🇺🇸 FDA
Pipeline program

GB-0669

GB-0669-101

Phase 1 small_molecule completed

Quick answer

GB-0669 for SARS CoV-2 is a Phase 1 program (small_molecule) at Generate Biomedicines with 1 ClinicalTrials.gov record(s).

Program details

Company
Generate Biomedicines
Indication
SARS CoV-2
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials